Phathom Pharmaceuticals, Inc. (PHAT) company profile
Close on Nov 13, 2026Market cap $492.63MP/E –Yield –
About Phathom Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to commercializing and developing therapeutic treatments for gastrointestinal diseases. The company offers vonoprazan-based acid blockers, including VOQUEZNA tablets for gastroesophageal reflux disease indications such as Erosive GERD and Non-Erosive GERD heartburn, as well as combination therapies for Helicobacter pylori infection alongside antibiotics under the brands VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK. Its primary customers are patients prescribed therapies for gastrointestinal conditions through healthcare providers such as gastroenterologists.
The enterprise operates as a single reporting segment centered on commercializing gastrointestinal therapies within the United States, while holding license rights covering European and Canadian markets. The company maintains commercial healthcare coverage spanning more than 120 million covered lives across America. Phathom Pharmaceuticals maintains its principal executive offices and headquarters in Florham Park, New Jersey.
Summary of the business section of Phathom Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Phathom Pharmaceuticals, Inc.
- Headquarters
- Florham Park, NJ
- Address
- 100 Campus Drive,, Suite 102 07932
- Phone
- (877) 742-8466
- Website
- phathompharma.com
- Employees
- 371, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- PHAT
- Exchange
- Nasdaq
- IPO date
- Oct 28, 2019
- Shares outstanding
- 81M, Oct 27, 2026
- Public float
- $555.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1783183
- CUSIP
- 71722W107
- ISIN
- US71722W1071
- FIGI
- BBG00P5B2S19
- Share class FIGI
- BBG00P5B2S73
- EIN
- 82-4151574
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven L. Basta | President and CEO, Director | 373,315 |
| Terrie Curran | President and Chief Executive, Director | 364,305 |
| Sanjeev Narula | Chief Financial & Bus. Officer | 215,841 |
| Robert Charles Breedlove | Principal Accounting Officer | 67,657 |
| Anne Marie Cook | Chief Legal Off. & Corp. Sec. | 88,660 |
| Molly Henderson | CFO and CBO | 91,779 |
| Azmi Nabulsi | Chief Operating Officer | 1,101,869 |
| Asit Parikh | Director | 172,622 |
| Mark Stenhouse | Director | 54,122 |
| Heidi Fields | Director | 54,122 |
| Michael F. Cola | Director | 63,920 |
| James N. Topper | Director | 5,957,449 |
| Theodore R. Schroeder | Director | 45,122 |
| Frank Karbe | Director | 91,622 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Steven Basta | $6.97M | $24.38M | $2.81M | $148 | – |
| FY2025 Terrie Curran | $4.94M | -$356.11K | $2.81M | $148 | – |
| FY2024 | $3.56M | $3.76M | $1.50M | $72 | – |
| FY2023 | $3.41M | $2.46M | $1.95M | $81 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Steven Basta President and Chief Executive Officer | $525.00K | $1.99M | $3.98M | $455.70K | $17.63K | $6.97M | – |
| Sanjeev Narula Chief Financial and Business Officer | $131.44K | $1.67M | $1.73M | $81.49K | $7.19K | $3.62M | – |
| Anne Marie Cook Chief Legal Officer and Secretary | $261.49K | $199.92K | $1.48M | $145.91K | $16.73K | $2.10M | – |
| Terrie Curran Former President and Chief Executive Officer | $184.00K | $473.47K | $1.45M | – | $2.83M | $4.94M | +38% |
| Azmi Nabulsi, M.D., M.P.H. Former Chief Operating Officer | $219.75K | $532.22K | $232.08K | – | $1.73M | $2.71M | +73% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 28, 2019
- Offer price
- $19.00
- Securities offered
- 9,563,157
- Gross proceeds
- $181.70M
- Exchange
- Nasdaq
- First trading day
- Oct 25, 2019
- First-day close
- $24.60+29.5%
- Lock-up ends (est.)
- Apr 22, 2020
“The initial public offering price per share is $19.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 371 full-time employees, some of whom hold a Ph.D., M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 2, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 28, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 16, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?